Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator

PURPOSE: There has been no extensive study to compare the efficacy between rituximab originator (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Here, we investigated the clinical effects of rituximab on poor outcomes of MPA and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Yonsei Med J
Hlavní autoři: Kwon, Hyeok Chan, Kim, Minyoung Kevin, Song, Jason Jungsik, Park, Yong-Beom, Lee, Sang-Won
Médium: Artigo
Jazyk:Inglês
Vydáno: Yonsei University College of Medicine 2020
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7393299/
https://ncbi.nlm.nih.gov/pubmed/32734735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2020.61.8.712
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky